New Drug Review and Approval Testing: Analytical Support for Regulatory Submissions

New drug review and approval testing provides the scientific evidence that regulatory authorities require to evaluate the quality, safety, and efficacy of investigational medicines before they enter clinical trials or reach the market. From CMC quality studies and impurity profiling to stability testing and bioanalysis, accredited third-party laboratories deliver validated data packages that support IND, NDA, ANDA, and BLA submissions worldwide. This article outlines the scope of testing, sample types, analytical methods, and regulatory applications involved in the new drug review and approval process.

Technical Overview

New drug review and approval testing encompasses the full range of analytical, microbiological, and biological studies that generate the quality data required by regulatory authorities when evaluating an application to initiate clinical trials or authorize marketing. Under frameworks such as the Investigational New Drug (IND) application, the Clinical Trial Application (CTA) in the European Union, and the New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA) that precede commercialization, sponsors must demonstrate that the drug substance and drug product are consistently manufactured, thoroughly characterized, and stable throughout their proposed shelf life.

The technical foundation of these submissions is the Quality section (Chemistry, Manufacturing, and Controls, or CMC) of the Common Technical Document (CTD), typically presented as Module 3. Testing programs are structured around the quality guideline series issued by the International Council for Harmonisation (ICH), including Q1 for stability testing, Q2 for analytical validation, Q3 for impurities, Q5 for biological products, Q6 for specifications, Q7 for GMP applicable to active pharmaceutical ingredients, Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for the pharmaceutical quality system. Safety studies intended for submission must be conducted under Good Laboratory Practice (GLP), while commercial batch release testing is performed under Good Manufacturing Practice (GMP).

Accredited third-party laboratories support sponsors by providing method development and validation, batch release testing, stability storage and testing, impurity identification, extractables and leachables analysis, and bioanalytical services. All work is expected to comply with data integrity principles (ALCOA+: attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available), because regulatory inspectors routinely audit raw data, audit trails, and electronic records supporting the submission.

Testing Samples

Registration testing covers every material that influences the quality of the finished medicine. The principal sample categories submitted for evaluation include:

Drug Substances (Active Pharmaceutical Ingredients)

• Laboratory, pilot, and commercial-scale API batches used to establish specifications and demonstrate process consistency.
• Process intermediates and starting materials subjected to structural confirmation and impurity carry-over assessment.
• APIs from alternative or relocated synthesis routes used in comparability and bridging exercises.

Drug Products and Dosage Forms

• Immediate-release and modified-release solid oral dosage forms such as tablets, capsules, and granules.
• Sterile products including injections, lyophilized powders, and ophthalmic preparations.
• Liquids, suspensions, emulsions, semisolids, inhalation products, and transdermal delivery systems.

Excipients, Intermediates, and Packaging Components

• Excipients, including novel excipients requiring full qualification packages.
• Primary packaging and delivery device components evaluated through extractables and leachables studies.
• Process-related materials such as catalysts, filtering aids, and cleaning agents assessed for residual contamination.

Reference Standards and Biological Matrices

• Qualified reference standards, impurity markers, and internal standards characterized for identity, purity, and assignment of content.
• Plasma, serum, urine, and tissue samples collected during pharmacokinetic, bioavailability, and bioequivalence studies.
• Cell banks, virus seeds, and critical reagents supporting biological product characterization.

Testing Items

The testing portfolio for a new drug application is built around the specification attributes defined in ICH Q6A and Q6B, supplemented by development-stage characterization work. Core testing items include:

• Identification and structural confirmation using infrared spectroscopy, ultraviolet spectroscopy, nuclear magnetic resonance, mass spectrometry, and chromatographic retention behavior.
• Assay of the active ingredient and content uniformity or fill weight verification for unit-dose products.
• Related substances profiling, including process impurities, degradation products, and forced-degradation markers, with reporting, identification, and qualification thresholds aligned to ICH Q3A and Q3B.
• Residual solvents controlled according to ICH Q3C, typically by headspace gas chromatography.
• Elemental impurities evaluated against ICH Q3D permit daily exposure limits using ICP-MS or ICP-OES.
• Mutagenic and genotoxic impurity risk assessment and control in accordance with ICH M7, including nitrosamine investigations.
• Physicochemical characterization: pH, osmolality, water content, specific optical rotation, particle size distribution, polymorphic form, and crystallinity.
• Dissolution and drug release profiling, disintegration time, and multipoint dissolution comparisons for biowaiver justification.
• Microbiological attributes: sterility, bacterial endotoxins, bioburden, antimicrobial effectiveness, and objectionable organism screening.
• Stability studies covering stress testing, accelerated, intermediate, and long-term conditions as well as photostability per ICH Q1A and Q1B, plus in-use and container-closure stability.
• Bioanalytical testing for pharmacokinetic concentration data, anti-drug antibodies, neutralizing antibodies, and biomarkers validated per regulatory bioanalytical method validation guidance.
• Biological potency assays, including cell-based bioassays, binding assays, and enzyme activity tests for biologics.
• Extractables and leachables studies performed under ICH Q3E concepts and compendial containers guidance.

Testing Methods

Regulatory-grade testing relies on compendial and validated in-house procedures. Compendial methods from the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), and the Chinese Pharmacopoeia (ChP) are verified before use, while non-compendial methods must be fully validated in accordance with ICH Q2(R2), demonstrating specificity, linearity, range, accuracy, precision, detection limit, quantitation limit, and robustness.

• Liquid chromatography (HPLC and UPLC) coupled with UV, diode array, fluorescence, refractive index, charged aerosol, or evaporative light scattering detection for assay and impurity quantitation.
• Liquid chromatography tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (Q-TOF, Orbitrap) for trace-level impurities, nitrosamines, and bioanalytical quantitation.
• Gas chromatography with flame ionization detection and headspace GC-MS for residual solvents and volatile impurities.
• Fourier-transform infrared spectroscopy, UV-Vis spectrophotometry, NMR, and mass spectrometry for identity confirmation.
• Inductively coupled plasma mass spectrometry and optical emission spectrometry for elemental impurities; ion chromatography for counterions and inorganic residues.
• Solid-state techniques including X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, and dynamic vapor sorption for polymorph and hydrate characterization.
• Karl Fischer titration for water content; laser diffraction and microscopic image analysis for particle size and morphology.
• Dissolution testing using compendial apparatus, with profile comparison by similarity factor and model-independent statistical approaches.
• Method transfer, co-validation, and comparative studies documented under formal protocols with predefined acceptance criteria.

Applications

Testing data generated for review and approval purposes directly supports multiple regulatory milestones across the product lifecycle:

• IND and CTA submissions, where sufficient quality data must demonstrate that clinical trial materials are safe for human administration.
• NDA and BLA submissions, providing the complete CMC package, specification justification, control strategy, and stability data establishing the proposed shelf life and storage conditions.
• ANDA submissions for generics, including bioequivalence support, dissolution profile comparisons, and polymorph or impurity equivalence arguments.
• Post-approval variations and supplements, such as manufacturing site changes, scale-up, formulation optimization, and specification updates, supported by comparability protocols.
• Expedited development pathways, where accelerated stability programs and rapid impurity qualification timelines align with breakthrough therapy or priority review designations.
• Compatibility studies linking drug substance properties with excipient selection and packaging choices during pharmaceutical development under ICH Q8.

FAQ

What guidelines govern new drug review and approval testing?

The primary framework is the ICH quality guideline series (Q1 through Q14), complemented by GMP and GLP regulations, pharmacopoeial standards such as USP, Ph. Eur., JP, and ChP, and regional regulatory guidance issued by authorities such as the FDA, EMA, NMPA, and PMDA. Together these documents define study design, validation expectations, specification setting, and data presentation in the CTD format.

Which studies are typically required before an IND filing?

An IND-enabling package generally includes API structure confirmation, preliminary impurity profiling, forced-degradation studies, a two-to-four-week accelerated stability indication, batch analysis of clinical trial material, and microbiological testing for sterile or aqueous products, along with GLP toxicology support data. Full shelf-life data is not mandatory at this stage but must be committed to and updated as development proceeds.

How long do registration stability studies take?

Long-term stability studies typically run for the full proposed shelf life, often 24 to 36 months, with accelerated studies completed within six months. Because review occurs while real-time studies continue, regulators generally require at least twelve months of long-term data at the time of an original NDA submission for new chemical entities.

Do analytical methods used in the submission need to be validated?

Yes. Compendial methods must be verified as suitable for the specific matrix, and all non-compendial methods require full validation under ICH Q2(R2). For biologics, bioanalytical and potency assays must additionally meet regulatory bioanalytical method validation expectations covering selectivity, sensitivity, accuracy, precision, recovery, and stability.

What role do accredited third-party laboratories play in the process?

Accredited third-party laboratories provide independent testing capacity, specialized instrumentation, GLP and GMP-compliant facilities, and regulatory experience that complement the sponsor's internal capabilities. Their reports, chromatograms, spectra, and raw data form part of the submission package and must withstand regulatory inspection and data integrity audits.

How are nitrosamine and mutagenic impurity risks addressed?

Risk assessments follow ICH M7 principles, combining structural alert analysis, computational toxicology evaluation, and confirmatory trace analysis by LC-MS/MS or GC-MS at parts-per-billion sensitivity. Where risks are confirmed, control strategies with justified acceptance limits and routine monitoring methods are established and documented in the submission.